Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults

Nasamon Wanlapakorn, View ORCID ProfileNungruthai Suntronwong, Harit Phowatthanasathian, View ORCID ProfileRitthideach Yorsaeng, Preeyaporn Vichaiwattana, Thanunrat Thongmee, Chompoonut Auphimai, Donchida Srimuan, Thaksaporn Thatsanatorn, Suvichada Assawakosri, Sitthichai Kanokudom, Natthinee Sudhinaraset, View ORCID ProfileYong Poovorawan
doi: https://doi.org/10.1101/2021.11.04.21265908
Nasamon Wanlapakorn
1Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nungruthai Suntronwong
1Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Nungruthai Suntronwong
Harit Phowatthanasathian
1Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ritthideach Yorsaeng
1Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ritthideach Yorsaeng
Preeyaporn Vichaiwattana
1Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thanunrat Thongmee
1Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chompoonut Auphimai
1Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Donchida Srimuan
1Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thaksaporn Thatsanatorn
1Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Suvichada Assawakosri
1Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sitthichai Kanokudom
1Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Natthinee Sudhinaraset
1Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yong Poovorawan
1Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand
2FRS(T), the Royal Society of Thailand, Sanam Sueapa, Dusit, Bangkok 10330, Thailand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Yong Poovorawan
  • For correspondence: yong.p@chula.ac.th
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

In light of intermittent supply shortages of individual vaccines and evidence of rare but serious adverse events after vaccination, heterologous regimens for COVID-19 vaccines have gained significant interest. This study aims to assess the reactogenicity and immunogenicity of the heterologous adenoviral vector vaccine regimen (ChAdOx1-S, AstraZeneca; hereafter referred to as AZ) and the inactivated vaccine regimen (CoronaVac; hereafter referred to as CV) regimen in healthy Thai adults immunized between June and September 2021. Our study showed that adverse events following homologous CV-CV and AZ-AZ, and heterologous CV-AZ and AZ-CV combinations, were mild and well tolerated overall. Receptor-binding domain (RBD)-specific antibody responses and neutralizing activities against wild-type and variants of concern after two-dose vaccination were higher in the heterologous CV-AZ and homologous AZ-AZ groups compared to the CV-CV and AZ-CV groups. Conversely, the spike-specific IgA response was detected only in the CV-AZ group after two doses of vaccination. The total interferon gamma response was detected in both the CV-AZ and AZ-CV groups after the two-dose vaccination. Given the shorter completion time of two doses, heterologous CoronaVac followed by ChAdOx1-S can be considered as an alternative regimen to homologous efficacy-proven ChAdOx1-S in countries with circulating variants. Additional studies on the efficacy and durability of immune responses induced by heterologous vaccine regimens are warranted.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

TCTR20210319003 TCTR20210628005

Funding Statement

This work was supported by The National Research Council of Thailand (NRCT), Health Systems Research Institute (HSRI), The Center of Excellence in Clinical Virology of Chulalongkorn University, and King Chulalongkorn Memorial Hospital.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study protocols were approved by the Institutional Review Board (IRB) of the Chulalongkorn University Faculty of Medicine (IRB numbers 192/64 and 491/64). Written informed consent was obtained from all participants prior to collecting clinical data and samples. This study is conducted in accordance with the Helsinki Declaration of 1975.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • In the revised MS, the new author "Natthinee Sudhinaraset" has been added in the authorship list.

Data Availability

All data produced in the present work are contained in the manuscript.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted November 07, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults
Nasamon Wanlapakorn, Nungruthai Suntronwong, Harit Phowatthanasathian, Ritthideach Yorsaeng, Preeyaporn Vichaiwattana, Thanunrat Thongmee, Chompoonut Auphimai, Donchida Srimuan, Thaksaporn Thatsanatorn, Suvichada Assawakosri, Sitthichai Kanokudom, Natthinee Sudhinaraset, Yong Poovorawan
medRxiv 2021.11.04.21265908; doi: https://doi.org/10.1101/2021.11.04.21265908
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults
Nasamon Wanlapakorn, Nungruthai Suntronwong, Harit Phowatthanasathian, Ritthideach Yorsaeng, Preeyaporn Vichaiwattana, Thanunrat Thongmee, Chompoonut Auphimai, Donchida Srimuan, Thaksaporn Thatsanatorn, Suvichada Assawakosri, Sitthichai Kanokudom, Natthinee Sudhinaraset, Yong Poovorawan
medRxiv 2021.11.04.21265908; doi: https://doi.org/10.1101/2021.11.04.21265908

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Allergy and Immunology
Subject Areas
All Articles
  • Addiction Medicine (214)
  • Allergy and Immunology (495)
  • Anesthesia (106)
  • Cardiovascular Medicine (1091)
  • Dentistry and Oral Medicine (194)
  • Dermatology (141)
  • Emergency Medicine (274)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (497)
  • Epidemiology (9747)
  • Forensic Medicine (5)
  • Gastroenterology (480)
  • Genetic and Genomic Medicine (2299)
  • Geriatric Medicine (221)
  • Health Economics (461)
  • Health Informatics (1548)
  • Health Policy (729)
  • Health Systems and Quality Improvement (600)
  • Hematology (236)
  • HIV/AIDS (500)
  • Infectious Diseases (except HIV/AIDS) (11623)
  • Intensive Care and Critical Care Medicine (615)
  • Medical Education (236)
  • Medical Ethics (67)
  • Nephrology (256)
  • Neurology (2137)
  • Nursing (133)
  • Nutrition (332)
  • Obstetrics and Gynecology (424)
  • Occupational and Environmental Health (516)
  • Oncology (1171)
  • Ophthalmology (363)
  • Orthopedics (128)
  • Otolaryngology (220)
  • Pain Medicine (145)
  • Palliative Medicine (50)
  • Pathology (308)
  • Pediatrics (693)
  • Pharmacology and Therapeutics (298)
  • Primary Care Research (265)
  • Psychiatry and Clinical Psychology (2168)
  • Public and Global Health (4640)
  • Radiology and Imaging (775)
  • Rehabilitation Medicine and Physical Therapy (451)
  • Respiratory Medicine (622)
  • Rheumatology (273)
  • Sexual and Reproductive Health (224)
  • Sports Medicine (208)
  • Surgery (250)
  • Toxicology (42)
  • Transplantation (120)
  • Urology (94)